AeroNeph Therapeutics (“AeroNeph”; www.aeronephtx.com), a pioneer in discovery of renal disease assets, has announced its MBO and corporate launch in the USA.
Guangzhou Doublle Bioproduct gives a clinical and commercial update on its Adenolysin gene therapy asset for head and neck cancer as its seeks global partners